

REGENERON

January 9, 2017

Sanofi and Regeneron Provide Update on Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection

Today the district court denied our motion to suspend the injunction, thus clearing the way for us to take our case to the Federal Circuit Court of Appeals. We will soon file a motion with the appellate court, asking it to suspend the injunction during the appeal process. Notably, the district court has delayed imposition of the injunction for an extra 15 days (for a total of 45 days from January 5) to allow Sanofi and Regeneron time to appeal.